【AH互动】百济神州(06160)AH股齐上扬百泽安新适应症上市许可申请获受理

凤凰网港股2022-06-22

百济神州(06160)连续第四日走强，早盘续升6.25%，报97.7元，成交额3598.94万元。另外，百济神州A股(688235)亦同步上行，但升幅较H股稍逊，最新报100元人民币，涨2.94%，成交额5550.25万元人民币。集团公布，公司近日收到国家药品监督管理局签发的《受理通知书》，百泽安(替雷利珠单抗注射液)用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部(G/GEJ)腺癌患者的新适应症上市许可申请获得受理。据悉，百泽安是一款人源化IgG4抗程序性死亡受体-1(PD-1)单克隆抗体，设计目的是为最大限度地减少与巨噬细胞中的Fcγ受体结合，帮助人体免疫细胞检测和对抗肿瘤。临床前数据表明，巨噬细胞中的Fcγ受体结合之后会激活抗体依赖细胞介导杀伤T细胞，从而降低了PD-1抗体的抗肿瘤活性。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2245426799?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-06-22 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2245426799","market":"hk","top_or_hot":-1,"title":"【AH互动】百济神州(06160)AH股齐上扬 百泽安新适应症上市许可申请获受理","media":"凤凰网港股","content":"<html><body><p><a href=\"https://laohu8.com/S/BGNE\">百济神州</a>(06160)连续第四日走强，早盘续升6.25%，报97.7元，成交额3598.94万元。另外，<a href=\"https://laohu8.com/S/688235\">百济神州</a>A股(688235)亦同步上行，但升幅较H股稍逊，最新报100元人民币，涨2.94%，成交额5550.25万元人民币。集团公布，公司近日收到国家药品监督管理局签发的《受理通知书》，百泽安(替雷利珠单抗注射液)用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部(G/GEJ)腺癌患者的新适应症上市许可申请获得受理。据悉，百泽安是一款人源化IgG4抗程序性死亡受体-1(PD-1)单克隆抗体，设计目的是为最大限度地减少与巨噬细胞中的Fcγ受体结合，帮助人体免疫细胞检测和对抗肿瘤。临床前数据表明，巨噬细胞中的Fcγ受体结合之后会激活抗体依赖细胞介导杀伤T细胞，从而降低了PD-1抗体的抗肿瘤活性。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【AH互动】百济神州(06160)AH股齐上扬 百泽安新适应症上市许可申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【AH互动】百济神州(06160)AH股齐上扬 百泽安新适应症上市许可申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-22 09:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://hknews.szfuit.com/newRssInfo/feed?original_id=45b884e065c037310dc8f424b47975a6><strong>凤凰网港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>百济神州(06160)连续第四日走强，早盘续升6.25%，报97.7元，成交额3598.94万元。另外，百济神州A股(688235)亦同步上行，但升幅较H股稍逊，最新报100元人民币，涨2.94%，成交额5550.25万元人民币。集团公布，公司近日收到国家药品监督管理局签发的《受理通知书》，百泽安(替雷利珠单抗注射液)用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部(G/GEJ)腺癌...</p>\n\n<a href=\"http://hknews.szfuit.com/newRssInfo/feed?original_id=45b884e065c037310dc8f424b47975a6\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=45b884e065c037310dc8f424b47975a6","article_id":"2245426799","we_media_id":"1002821290","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2245426799","pubTimestamp":1655861902,"sourceInfo":null,"weMediaInfo":{"media_name":"凤凰网港股","introduction":"凤凰网港股","home_visible":1,"id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"summary":"集团公布，公司近日收到国家药品监督管理局签发的《受理通知书》，百泽安用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部腺癌患者的新适应症上市许可申请获得受理。临床前数据表明，巨噬细胞中的Fcγ受体结合之后会激活抗体依赖细胞介导杀伤T细胞，从而降低了PD-1抗体的抗肿瘤活性。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","BK4526":"热门中概股","BK4139":"生物科技","BK4504":"桥水持仓","06160":"百济神州","BK1583":"高瓴概念","BK1588":"回港中概股","BK4548":"巴美列捷福持仓","BK1500":"做空集合股","BGNE":"百济神州","BK4535":"淡马锡持仓","BK1161":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"[AH Interactive] Baekje Shenzhou (06160) AH shares rose together. The application for listing license for new indications of Baize'an was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"06160":1,"AH":1,"BGNE":1},"content_text":"百济神州(06160)连续第四日走强，早盘续升6.25%，报97.7元，成交额3598.94万元。另外，百济神州A股(688235)亦同步上行，但升幅较H股稍逊，最新报100元人民币，涨2.94%，成交额5550.25万元人民币。集团公布，公司近日收到国家药品监督管理局签发的《受理通知书》，百泽安(替雷利珠单抗注射液)用于一线治疗肿瘤表达PD-L1的晚期或转移性胃或胃食管结合部(G/GEJ)腺癌患者的新适应症上市许可申请获得受理。据悉，百泽安是一款人源化IgG4抗程序性死亡受体-1(PD-1)单克隆抗体，设计目的是为最大限度地减少与巨噬细胞中的Fcγ受体结合，帮助人体免疫细胞检测和对抗肿瘤。临床前数据表明，巨噬细胞中的Fcγ受体结合之后会激活抗体依赖细胞介导杀伤T细胞，从而降低了PD-1抗体的抗肿瘤活性。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2245426799"}

【AH互动】百济神州(06160)AH股齐上扬 百泽安新适应症上市许可申请获受理

精彩评论

【AH互动】百济神州(06160)AH股齐上扬百泽安新适应症上市许可申请获受理